Description

Phase 2 Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Cardiovascular Disease

This is a study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG) levels in patients with hypertriglyceridemia and established cardiovascular disease (CVD).

Principal Investigator: Christie Ballantyne, M.D.

For more information, please contact:

Sharon Goss
Phone: (713) 798-8800 
Email: sgoss@bcm.edu

Terry Techmanski, RN
Phone: (713) 798-5845 
Email: maryt@bcm.edu

Contact

Sharon Goss sgoss@bcm.eduPhone 1: (713) 798-8800
IRB: h-42888

Status

Active

Created

Apr 05, 2018